Section

Medicine

Clinical care, research, FDA

New York Post

Understanding Polyendocrine Metabolic Ovarian Syndrome: Diagnosis and Myths

Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), affects 1 in 8 women of reproductive age and is often misdiagnosed due to its varied symptoms. The condition is complex and requires individualized treatment. Ongoing monitoring is essential for managing health risks associated with PMOS.

Bias: 30 Sentiment: +0.00
Daily Mail

Study suggests breast cancer survivors may not need lifelong heart medication

A trial suggests that most breast cancer survivors who developed heart problems due to treatment may not need lifelong medication. The study found that 98% of participants who stopped taking heart drugs showed no decline in heart function after one year. The findings provide hope for improved quality of life for these survivors.

Bias: 30 Sentiment: +0.50
Washington Examiner

FDA Approves First mRNA Influenza Vaccine; Positive Results for mRNA Cancer Treatment Announced

The FDA has approved MFLUSIVA, the first mRNA influenza vaccine for adults aged 50 and older, and announced positive Phase 3 results for an mRNA cancer treatment for melanoma. These developments highlight the evolving landscape of mRNA technology in medicine, though further scrutiny and peer review are necessary before definitive conclusions can be drawn.

Bias: 65 Sentiment: +0.10
PBS NewsHour

FDA Approves New Drug for Advanced Pancreatic Cancer; Developments in Cancer Vaccines

The FDA has approved a new drug, daraxonrasib, for advanced pancreatic cancer, which has shown to nearly double patient survival times. Additionally, a new individualized mRNA vaccine for melanoma has demonstrated positive results in clinical trials, potentially lowering relapse rates. Experts express optimism about the future of cancer treatments and vaccines.

Bias: 4 Sentiment: +0.50
BBC — World

FDA Approves New Treatment for Pancreatic Cancer

The FDA has approved daraxonrasib, a new treatment for pancreatic cancer, which has shown to nearly double patient survival times in clinical trials. The drug targets the mutated KRAS gene, prevalent in many pancreatic tumors, and offers a new option for patients facing this challenging cancer. Common side effects include rash and nausea, with a lower incidence of severe side effects compared to chemotherapy.

Bias: 4 Sentiment: +0.10
The Hill

FDA Approves New Treatment for Advanced Pancreatic Cancer

The FDA has approved daraxonrasib, a new once-daily pill for advanced pancreatic cancer, providing a new treatment option for patients who have not responded to previous therapies. The drug is produced by Revolution Medicines and will be sold under the brand name Rasonque.

Bias: 4 Sentiment: +0.50
Daily Wire

FDA Approves New Treatment for Advanced Pancreatic Cancer

The FDA has approved daraxonrasib, branded as Rasonque, for the treatment of advanced pancreatic cancer. The approval follows a clinical trial showing that the drug nearly doubled median survival rates compared to standard chemotherapy. Experts highlight the significance of this treatment for patients with metastatic pancreatic adenocarcinoma.

Bias: 4 Sentiment: +0.50
Wired

Study Identifies Genetic Mutation Linked to Drug-Resistant Malaria

A study by Brown University researchers has identified a genetic mutation in malaria parasites that may contribute to drug resistance. The mutation, named PIN, has rapidly spread in Uganda, showing reduced sensitivity to common antimalarial drugs. The findings underscore the need for enhanced surveillance and the development of new treatments.

Bias: 4 Sentiment: +0.00
Hacker News — Front Page

FDA authorizes wearable device for monitoring ketone and blood sugar levels

The FDA has authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System, the first device to continuously monitor both ketone and blood sugar levels for individuals aged 2 and older with diabetes. The device provides real-time data and alerts to help prevent diabetic ketoacidosis, a serious complication of diabetes.

Bias: 4 Sentiment: +0.10
Fox News — Latest

Study links tadalafil use to increased risk of glaucoma

A recent study suggests that long-term use of tadalafil, a medication for erectile dysfunction, may increase the risk of glaucoma. The research analyzed health records of nearly 74,000 men and found that those using tadalafil had a higher likelihood of developing glaucoma and elevated intraocular pressure. Experts recommend regular eye exams for those at risk.

Bias: 4 Sentiment: +0.00
Fox News — Latest

Clinical Trial Shows Promising Results for mRNA Skin Cancer Vaccine

A clinical trial for an experimental skin cancer vaccine by Merck and Moderna has shown significant results in reducing melanoma recurrence and spread. The trial involved 1,137 patients and demonstrated improved survival rates for those receiving the personalized mRNA vaccine alongside standard treatment. Regulatory discussions are planned following these promising findings.

Bias: 14 Sentiment: +0.20
Fox News — Latest

Study reveals increased wait times for cancer treatment in the U.S.

A recent study published in JAMA Surgery found that wait times for cancer treatment in the U.S. have increased by nearly two weeks over the past decade, with significant delays noted for certain cancer types. The study analyzed data from over two million patients and highlighted disparities in wait times among different demographic groups. Experts emphasize the need for improvements in the healthcare system to address these delays.

Bias: 30 Sentiment: -0.10
Fox News — Latest

Study Finds Estrogen-Only Menopausal Hormone Therapy Linked to Lower Alzheimer's Risk

A Stanford study published in Neurology suggests that estrogen-only menopausal hormone therapy may lower the risk of Alzheimer's-related brain changes and dementia in women. The study analyzed data from over 21,000 participants and found that those using estrogen-only therapy had a significantly reduced likelihood of developing Alzheimer's pathology and dementia. The researchers call for further clinical trials to confirm these findings.

Bias: 14 Sentiment: +0.20
yahoo.com

Rising Use of Banned Peptides Among Bodybuilders Raises Health Concerns

The use of banned peptides among bodybuilders is increasing, with individuals injecting substances like GHK-Cu and Retatrutide for perceived benefits. Experts warn of serious health risks due to a lack of evidence supporting these claims and the absence of safety guidelines. Recent discussions in the U.S. about loosening restrictions on peptides have raised concerns among medical professionals.

Bias: 33 Sentiment: -0.20
Axios

Study finds AI can improve efficiency in clinical trials for cancer treatments

A Tufts Center study reveals that AI can significantly improve the efficiency of clinical trials for cancer treatments, potentially reducing trial time by 10 weeks and costs by up to $5.6 million. The technology may become standard in trials within three to five years, although challenges in patient recruitment and consent persist.

Bias: 4 Sentiment: +0.10
Fox News — Politics

Fauci Discusses COVID-19 mRNA Vaccine Concerns for Pregnant Women in Released Texts

Dr. Anthony Fauci discussed concerns about COVID-19 mRNA vaccines for pregnant women in January 2021, as revealed in text messages released by a Senate committee. The conversations included discussions on potential risks associated with vaccination timing and symptoms after the second dose, as well as the need to balance vaccination risks with COVID-19 risks.

Bias: 4 Sentiment: +0.00
NPR — Top Stories

Medical Bias Affects Treatment for Addiction Patients

Jean Descamps, a 26-year-old man, died shortly after being discharged from Providence Milwaukie Hospital in December 2023. Reports highlight that addiction treatments, while safe and effective, are not commonly offered due to prevailing biases among healthcare professionals against patients with substance use disorders.

Bias: 4 Sentiment: -0.20
The Daily Beast

Study Suggests GLP-1 Medications May Lower Risk of Age-Related Macular Degeneration

A study suggests that GLP-1 medications may lower the risk of age-related macular degeneration in older adults with obesity. The research indicates an 18% reduced risk for those taking GLP-1 drugs compared to other weight-loss medications, with the benefit potentially increasing to 30%. Further studies are needed to clarify the relationship between the medications and eye health.

Bias: 4 Sentiment: +0.10